AstraZeneca and MedImmune join chronic kidney disease consortium
AstraZeneca announced this week that it, along with its worldwide biologics research and development subsidiary, MedImmune, have entered into an agreement to partner with the University of Michigan and Eli Lilly to develop new therapeutic drugs to treat chronic kidney disease (CKD). Read More »
Alerts Sign-up